CEO Charles Gayer was paid $9,627,868 in fiscal year 2025, ↑ up 185.3% from fiscal year 2024, the 53rd percentile of its disclosed peer group (SEC filing 0001628280-26-026822 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$12,951,082 Jon Stonehouse total, FY2025 Former President and Chief Executive Officer — highest-paid officer; CEO Charles Gayer: $9,627,868 | 53rd CEO (Charles Gayer) pay percentile vs peers | 41:1 CEO-to-median pay ratio | 68.95% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
BCRX's next annual pay disclosure, estimated April 22, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jon Stonehouse | $728,466 | $0 | $0 | $11,132,458 | $1,052,633 | $0 | $37,525 | $12,951,082 |
| Former President and Chief Executive Officer | ||||||||
| Charles Gayer | 609,397 | 0 | 3,358,230 | 4,893,653 | 749,088 | 0 | 17,500 | 9,627,868 |
| President and Chief Executive Officer; Former Chief Commercial Officer | ||||||||
| Babar Ghias | 271,515 | 160,000 | 2,124,571 | 3,675,166 | 506,400 | 0 | 10,500 | 6,748,152 |
| Chief Financial Officer | ||||||||
| Alane Barnes | 542,519 | 0 | 867,721 | 3,634,923 | 553,369 | 0 | 17,500 | 5,616,032 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Helen Thackray | 425,999 | 0 | 1,168,791 | 1,255,458 | 756,112 | 0 | 733,264 | 4,339,624 |
| Former Chief Research and Development Officer | ||||||||
| Anthony Doyle | 151,925 | 0 | 708,694 | 1,165,816 | 0 | 0 | 114,700 | 2,141,135 |
| Former Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jon Stonehouse | $12,951,082 | $8,317,286 | $4,777,778 | ↑ +4,633,796 |
| Charles Gayer | 9,627,868 | 3,375,210 | 1,738,544 | ↑ +6,252,658 |
| Babar Ghias | 6,748,152 | — | — | — |
| Alane Barnes | 5,616,032 | 3,241,696 | 1,932,072 | ↑ +2,374,336 |
| Helen Thackray | 4,339,624 | 3,568,850 | 2,393,933 | ↑ +770,774 |
| Anthony Doyle | 2,141,135 | 3,287,271 | 1,790,349 | ↓ −1,146,136 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read BioCryst Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BCRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses BCRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BCRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| A. Machelle Sanders | Independent Director | $385,253 |
| Alan G. Levin | Independent Director | $397,496 |
| Amy E. McKee, M.D | Independent Director | $389,996 |
| George B. Abercrombie | Former director (through FY2025) | $30,598 |
| Jill C. Milne, Ph.D | Independent Director | — |
| Nancy J. Hutson, Ph.D | Former director (through FY2025) | $682,886 |
| Stephen J. Asalege | Former director (through FY2025) | — |
| Stephen J. Aselage | Independent Director | $33,475 |
| Steven K. Galson, M.D., MPH | Independent Director | $385,584 |
| Steven R. Frank | Independent Director | $396,489 |
| Theresa M. Heggie | Independent Director | $401,700 |
| Vincent J. Milano | Independent Director | $403,695 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alane Barnes | Chief Legal Officer | 2026-05-13 | D | 62,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Alane Barnes | Chief Legal Officer | 2026-05-13 | D | 62,500 | 10 | 596,250 | Common | Form 4 ↗ |
| Alane Barnes | Chief Legal Officer | 2026-05-13 | A | 62,500 | 5 | 315,000 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-05-18 | D | 11,180 | 9 | 100,285 | Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-05-29 | A | 1,262 | 9 | 11,244 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-05-29 | A | 1,122 | 9 | 9,997 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-05-29 | A | 631 | 9 | 5,622 | Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-05-29 | A | 631 | 9 | 5,622 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-05-29 | A | 1,262 | 9 | 11,244 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven K. Galson | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Theresa M. Heggie | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Theresa M. Heggie | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| A. Machelle Sanders | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| A. Machelle Sanders | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Alan G. Levin | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Levin | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Galson | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-08-31 | A | 1,288 | 10 | 12,494 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-08-31 | A | 644 | 10 | 6,247 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-08-31 | A | 1,159 | 10 | 11,242 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-08-31 | A | 1,288 | 10 | 12,494 | Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-08-31 | A | 644 | 10 | 6,247 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Charles Gayer | RSU | 2025-12-17 | — | — | 471,000 | — | $3,358,230 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 118,875 | — | 164,452 |
| Helen Thackray | RSU | 2025-08-07 | — | — | 62,975 | — | 525,841 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 40,000 | — | 13,811 |
| Helen Thackray | RSU | 2025-08-07 | — | — | 25,500 | — | 212,925 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 332,500 | — | 252,360 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 600,000 | — | 86,454 |
| Helen Thackray | RSU | 2025-08-07 | — | — | 40,500 | — | 338,175 |
| Anthony Doyle | RSU | 2025-05-31 | — | — | 18,750 | — | 201,563 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 40,000 | — | 2,858 |
| Anthony Doyle | RSU | 2025-05-31 | — | — | 30,175 | — | 324,381 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 574,500 | — | 2,360,815 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 297,500 | — | 957,934 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 305,995 | — | 3,341 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 675,000 | — | 1,349,613 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 629,000 | — | 286,333 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 500,000 | — | 278,800 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 870,000 | — | 2,890,014 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 300,000 | — | 267,672 |
| Babar Ghias | RSU | 2025-12-17 | — | — | 121,700 | — | 867,721 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 190,000 | — | 35,540 |
| Babar Ghias | OPTION | 2025-07-24 | — | — | 305,000 | — | 1,914,700 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 125,050 | — | 296,878 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 130,475 | — | 288,568 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 118,875 | — | 251,329 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 205,000 | — | 132,856 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 238,000 | — | 198,141 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 158,500 | — | 497,238 |
| Charles Gayer | OPTION | 2025-12-17 | — | — | 986,950 | — | 4,893,653 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 400,000 | — | 262,373 |
| Anthony Doyle | RSU | 2025-05-31 | — | — | 8,500 | — | 91,375 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 62,525 | — | 257,291 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 187,562 | — | 738,178 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 446,250 | — | 1,999,758 |
| Helen Thackray | RSU | 2025-08-07 | — | — | 11,000 | — | 91,850 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 62,500 | — | 10,316 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 63,762 | — | 171,200 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 190,000 | — | 134,720 |
| Alane Barnes | RSU | 2025-12-17 | — | — | 121,700 | — | 867,721 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 164,000 | — | 194,898 |
| Helen Thackray | OPTION | 2025-08-07 | — | — | 178,500 | — | 356,851 |
| Alane Barnes | OPTION | 2025-12-17 | — | — | 255,050 | — | 1,264,630 |
| Anthony Doyle | OPTION | 2025-05-31 | — | — | 79,250 | — | 210,361 |
| Babar Ghias | RSU | 2025-07-24 | — | — | 147,000 | — | 1,256,850 |
| Babar Ghias | OPTION | 2025-12-17 | — | — | 355,050 | — | 1,760,466 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 164,000 | — | 467,635 |
| Alane Barnes | OPTION | 2025-12-27 | — | — | 280,000 | — | 505,437 |
| Anthony Doyle | RSU | 2025-05-31 | — | — | 8,500 | — | 91,375 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Charles Gayer | $3,358,230 | $0 | $4,893,653 | 0.0% |
| Anthony Doyle | 708,694 | 0 | 1,165,816 | 0.0% |
| Helen Thackray | 1,168,791 | 0 | 1,255,458 | 0.0% |
| Jon Stonehouse | 0 | 0 | 11,132,458 | 0.0% |
| Babar Ghias | 2,124,571 | 0 | 3,675,166 | 0.0% |
| Alane Barnes | 867,721 | 0 | 3,634,923 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jon Stonehouse | Option | 148,750 | 10.63 | — |
| Alane Barnes | RSU | 32,000 | — | 249,600 |
| Alane Barnes | RSU | 121,700 | — | 949,260 |
| Alane Barnes | Option | 79,250 | 6.43 | — |
| Charles Gayer | RSU | 471,000 | — | 3,673,800 |
| Jon Stonehouse | RSU | 271,575 | — | 2,118,285 |
| Charles Gayer | Option | 986,950 | 7.13 | — |
| Babar Ghias | RSU | 147,000 | — | 1,146,600 |
| Babar Ghias | RSU | 121,700 | — | 949,260 |
| Charles Gayer | RSU | 94,463 | — | 736,811 |
| Alane Barnes | Option | 255,050 | 7.13 | — |
| Alane Barnes | RSU | 90,525 | — | 706,095 |
| Charles Gayer | Option | 39,625 | 10.63 | — |
| Jon Stonehouse | RSU | 63,750 | — | 497,250 |
| Jon Stonehouse | RSU | 31,875 | — | 248,625 |
| Charles Gayer | RSU | 17,000 | — | 132,600 |
| Alane Barnes | RSU | 8,500 | — | 66,300 |
| Charles Gayer | RSU | 8,500 | — | 66,300 |
| Jon Stonehouse | Option | 297,500 | 6.43 | — |
| Jon Stonehouse | Option | 562,688 | 7.39 | — |
| Babar Ghias | Option | 305,000 | 8.55 | — |
| Babar Ghias | Option | 355,050 | 7.13 | — |
| Alane Barnes | Option | 39,625 | 10.63 | — |
| Alane Barnes | Option | 187,575 | 7.39 | — |
| Charles Gayer | Option | 79,250 | 6.43 | — |
| Charles Gayer | Option | 195,713 | 7.39 | — |
Our goal is to provide a compensation package that attracts, incentivizes, and retains employees and is designed to align employees' interests with the Company's corporate strategies and business objectives and the interests of the stockholders.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 126,098,528 | 56,797,571 | 959,367 | 68.95% | Passed |
| 2025 | 2025-06-12 | 143,096,094 | 6,357,577 | 302,120 | 95.75% | Passed |
| 2024 | 2024-06-12 | 138,402,008 | 6,410,647 | 584,242 | 95.57% | Passed |
| 2023 | 2023-06-13 | 112,956,369 | 10,424,056 | 844,878 | 91.55% | Passed |
| 2022 | 2022-06-07 | 97,431,771 | 10,439,088 | 570,329 | 90.32% | Passed |
| 2021 | 2021-05-25 | 68,805,650 | 4,195,252 | 13,228,045 | 94.25% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 68.95%a |
| 2025 | 2025-06-12 | 95.75%b |
| 2024 | 2024-06-12 | 95.57%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect upon these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect upon these proposals.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect upon these proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 41 : 1 |
|---|---|
| CEO total compensation | $12,951,082 |
| Median employee compensation | $314,234 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy J. Hutson, Ph.DIndependent · Compensation · Not standing for re-election · Departed during FY | $103,817 | $225,500 | $353,569 | — | — | $682,886 |
| Vincent J. MilanoIndependent · Audit | 78,699 | 130,000 | 194,996 | — | — | 403,695 |
| Theresa M. HeggieIndependent · Audit · Corporate Governance and Nominating | 76,704 | 130,000 | 194,996 | — | — | 401,700 |
| Alan G. LevinIndependent · Audit (Chair) | 72,500 | 130,000 | 194,996 | — | — | 397,496 |
| Steven R. FrankIndependent · Finance | 29,835 | 146,663 | 219,991 | — | — | 396,489 |
| Amy E. McKee, M.DIndependent · Corporate Governance and Nominating | 65,000 | 130,000 | 194,996 | — | — | 389,996 |
| Steven K. Galson, M.D., MPHIndependent · Compensation · Corporate Governance and Nominating (Chair) | 60,588 | 130,000 | 194,996 | — | — | 385,584 |
| A. Machelle SandersIndependent · Compensation (Chair) | 60,257 | 130,000 | 194,996 | — | — | 385,253 |
| Stephen J. AselageIndependent | 33,475 | 0 | 0 | — | — | 33,475 |
| George B. AbercrombieIndependent · Not standing for re-election · Departed during FY | 30,598 | 0 | 0 | — | — | 30,598 |
| Jill C. Milne, Ph.DIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Charles K. GayerEmployee director | — | — | — | — | — | 0 |
| Jon P. StonehouseEmployee director | — | — | — | — | — | 0 |
| Stephen J. AsalegeNot standing for re-election · Departed during FY | — | 0 | 0 | — | — | — |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $325,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 10,000 |
| Stock ownership guideline | $135,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $611,473 |
| Equity awards (grant-date value) | $1,152,163 |
| All other compensation | $0 |
| Total cost of the board | $1,763,636 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies BioCryst Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including BioCryst Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Rhythm Pharmaceuticals | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 6 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 7 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 8 | ADMA Biologics | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 9 | BioCryst Pharmaceuticals | 2025 | Charles Gayer | 609,397 | 3,358,230 | 4,893,653 | 749,088 | 9,627,868 |
| 10 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 13 | ACADIA Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Harmony Biosciences | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 16 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 17 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 18 | SIGA Technologies | 2025 | Diem Nguyen | 927,000 | 1,853,992 | 0 | 0 | 3,244,492 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| BioCryst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| ACADIA Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| ADMA Biologics | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Harmony Biosciences | 100% | not disclosed | not disclosed | Pay Governance |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Mirum Pharmaceuticals | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Pacira BioSciences | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Rhythm Pharmaceuticals | 120% | Options 50 · RSU 50 | No | Pay Governance |
| SIGA Technologies | not disclosed | RSU 50 · PSU 50 | not disclosed | Pay Governance LLC |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jon Stonehouse | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 2 | Section 01, Charles Gayer | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 9,627,868. Filing ↗machine: r15 · c48 · span 552621–552630 |
| 3 | Section 01, Babar Ghias | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 6,748,152. Filing ↗machine: span 530989–530998 |
| 4 | Section 01, Alane Barnes | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 5,616,032. Filing ↗machine: span 543254–543263 |
| 5 | Section 01, Helen Thackray | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 4,339,624. Filing ↗machine: r9 · c48 · span 534208–534217 |
| 6 | Section 01, Anthony Doyle | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “SUMMARY COMPENSATION TABLE” · page 39. As printed: 2,141,135. Filing ↗machine: r5 · c48 · span 521804–521813 |
| 7 | Section 03, Charles Gayer RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 748633–748642 |
| 8 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 633521–633528 |
| 9 | Section 03, Helen Thackray RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 699490–699497 |
| 10 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 674877–674883 |
| 11 | Section 03, Helen Thackray RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 696802–696809 |
| 12 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 628145–628152 |
| 13 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 625459–625465 |
| 14 | Section 03, Helen Thackray RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 694114–694121 |
| 15 | Section 03, Anthony Doyle RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 641582–641589 |
| 16 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 672108–672113 |
| 17 | Section 03, Anthony Doyle RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 649645–649652 |
| 18 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 606529–606538 |
| 19 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 613286–613293 |
| 20 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 586244–586249 |
| 21 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 596396–596405 |
| 22 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 599774–599781 |
| 23 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 589644–589651 |
| 24 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 603150–603159 |
| 25 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 593020–593027 |
| 26 | Section 03, Babar Ghias RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 665623–665630 |
| 27 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 719366–719372 |
| 28 | Section 03, Babar Ghias OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 655820–655829 |
| 29 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 736247–736254 |
| 30 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 688739–688746 |
| 31 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 732871–732878 |
| 32 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 680422–680429 |
| 33 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 683195–683202 |
| 34 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 729495–729502 |
| 35 | Section 03, Charles Gayer OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 745939–745948 |
| 36 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 677649–677656 |
| 37 | Section 03, Anthony Doyle RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 644270–644276 |
| 38 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 638893–638900 |
| 39 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 616662–616669 |
| 40 | Section 03, Jon Stonehouse OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 609908–609917 |
| 41 | Section 03, Helen Thackray RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 691427–691433 |
| 42 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 712615–712621 |
| 43 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 739622–739629 |
| 44 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 715990–715997 |
| 45 | Section 03, Alane Barnes RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 709240–709247 |
| 46 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 630833–630840 |
| 47 | Section 03, Helen Thackray OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 685967–685974 |
| 48 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 705971–705980 |
| 49 | Section 03, Anthony Doyle OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 636207–636214 |
| 50 | Section 03, Babar Ghias RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 659088–659097 |
| 51 | Section 03, Babar Ghias OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 662354–662363 |
| 52 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 726118–726125 |
| 53 | Section 03, Alane Barnes OPTION | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 722741–722748 |
| 54 | Section 03, Anthony Doyle RSU | DEF 14A | 1900-01-01 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: span 646957–646963 |
| 55 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “CEO Pay Ratio”. As printed: 41 : 1. Filing ↗ |
| 56 | Section 08, Nancy J. Hutson, Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 682,886. Filing ↗machine: span 1061050–1061356 |
| 57 | Section 08, Vincent J. Milano | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 403,695. Filing ↗machine: span 1067185–1067491 |
| 58 | Section 08, Theresa M. Heggie | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 401,700. Filing ↗machine: span 1058965–1059271 |
| 59 | Section 08, Alan G. Levin | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 397,496. Filing ↗machine: span 1062938–1063244 |
| 60 | Section 08, Steven R. Frank | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 396,489. Filing ↗machine: span 1055171–1055477 |
| 61 | Section 08, Amy E. McKee, M.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 389,996. Filing ↗machine: span 1065062–1065368 |
| 62 | Section 08, Steven K. Galson, M.D., MPH | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 385,584. Filing ↗machine: span 1057073–1057379 |
| 63 | Section 08, A. Machelle Sanders | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 385,253. Filing ↗machine: span 1069079–1069385 |
| 64 | Section 08, Stephen J. Aselage | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 33,475. Filing ↗machine: span 1051699–1051940 |
| 65 | Section 08, George B. Abercrombie | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 30,598. Filing ↗machine: span 1049292–1049562 |
| 66 | Section 08, Jill C. Milne, Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 67 | Section 08, Charles K. Gayer | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 68 | Section 08, Jon P. Stonehouse | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 69 | Section 08, Stephen J. Asalege | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 70 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Amy E. McKee 2026-05-18 | Form 4 | 2026-05-19 | 0000882796-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Steven R. Frank 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Vincent J. Milano 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Amy E. McKee 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Jon P. Stonehouse 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jill C. Milne 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Amy E. McKee 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Jon P. Stonehouse 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jon P. Stonehouse 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Vincent J. Milano 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Steven R. Frank 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Steven R. Frank 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jill C. Milne 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Steven K. Galson 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Jill C. Milne 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Theresa M. Heggie 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Theresa M. Heggie 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Amy E. McKee 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Vincent J. Milano 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, A. Machelle Sanders 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, A. Machelle Sanders 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Alan G. Levin 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Alan G. Levin 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Steven K. Galson 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Steven R. Frank 2026-08-31 | Form 4 | 2026-09-02 | 0000882796-26-000057 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Amy E. McKee 2026-08-31 | Form 4 | 2026-09-02 | 0000882796-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Vincent J. Milano 2026-08-31 | Form 4 | 2026-09-02 | 0000882796-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Jill C. Milne 2026-08-31 | Form 4 | 2026-09-02 | 0000882796-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Jon P. Stonehouse 2026-08-31 | Form 4 | 2026-09-02 | 0000882796-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001171843-26-004096 | Item 5.07 · say-on-pay result. As reported: 68.95% (votes for as printed: 126,098,528). Filing ↗ |
| 103 | Section 06, 2025 vote | Form 8-K | 2025-06-16 | 0001171843-25-003910 | Item 5.07 · say-on-pay result. As reported: 95.75% (votes for as printed: 143,096,094). Filing ↗ |
| 104 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0001171843-24-003430 | Item 5.07 · say-on-pay result. As reported: 95.57% (votes for as printed: 138,402,008). Filing ↗ |
| 105 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 106 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 107 | Section 09b board cost (computed) | Computed | — | — | Cash 611,473 + equity 1,152,163 + all other 0 = 1,763,636, summed across the director compensation table rows.machine: formula: Σ = 1,763,636 |
| 108 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗ |
| 109 | Rhythm Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 110 | Corcept Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 111 | Insmed, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 112 | Pacira BioSciences, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 113 | Apellis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 114 | Mirum Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 115 | ADMA Biologics, Section 10b CEO total | DEF 14A | 2026-04-15 | 0001140361-26-014799 | CEO total compensation as printed in ADMA Biologics's own proxy. As printed: 10,237,326. Filing ↗machine: r2 · c25 · span 619658–619669 |
| 116 | BioCryst Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 9,627,868. Filing ↗machine: r15 · c48 · span 552621–552630 |
| 117 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 118 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 119 | Travere Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 120 | ACADIA Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗ |
| 121 | Dynavax Technologies, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗ |
| 122 | Harmony Biosciences, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 123 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 124 | Catalyst Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗ |
| 125 | SIGA Technologies, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017421 | CEO total compensation as printed in SIGA Technologies's own proxy. As printed: 3,244,492. Filing ↗machine: r2 · c24 · span 426609–426618 |
| 126 | Section 10a, ACADIA Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 127 | Section 10a, ADMA Biologics reciprocity | DEF 14A | — | 0001140361-26-014799 | ADMA Biologics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 128 | Section 10a, Dynavax Technologies reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 129 | Section 10a, Insmed reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 130 | Section 10a, Mirum Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 131 | Section 10a, Pacira BioSciences reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 132 | Section 10a, Travere Therapeutics reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 133 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 134 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 135 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 136 | Section 10a, Rhythm Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 137 | Section 10a, SIGA Technologies reciprocity | DEF 14A | — | 0001140361-26-017421 | SIGA Technologies's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 138 | Section 10a, Harmony Biosciences reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 139 | Section 10a, Apellis Pharmaceuticals reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 140 | Section 10a, Catalyst Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 141 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.